Vutrisiran Market by Drug Class, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033

<p>The global <strong>vutrisiran market</strong> garnered a market value of US$ 600 Million in 2022 and is expected to accumulate a market value of US$ 2,087 Million by registering a CAGR of 12% in the forecast period 2023 to 2033. The expansion of the market can be credited to Vutrisiran, which provides optimism and a fresh therapeutic choice for individuals who have hereditary transthyretin-mediated amyloidosis (hATTR). The market for vutrisiran registered a CAGR of 5.1% in the historical period 2018 to 2022</p><table><tbody><tr><th scope='row'>Report Attribute</th><td>Details</td></tr><tr><th scope='row'>Expected Market Value (2023)</th><td>US$ 671.96 Million</td></tr><tr><th scope='row'>Anticipated Forecast Value (2033)</th><td>US$ 2,087 Million</td></tr><tr><th scope='row'>Projected Growth Rate (2023 to 2033)</th><td>12% CAGR</td></tr></tbody></table><p>Report Scope</p><table><tbody><tr><th scope='row'>Report Attribute</th><td>Details</td></tr><tr><th scope='row'>Market Value in 2023</th><td>US$ 671.96 million</td></tr><tr><th scope='row'>Market Value in 2033</th><td>US$ 2,087 million</td></tr><tr><th scope='row'>Growth Rate</th><td>CAGR of 12% from 2023 to 2033</td></tr><tr><th scope='row'>Base Year for Estimation</th><td>2022</td></tr><tr><th scope='row'>Historical Data</th><td>2018 to 2022</td></tr><tr><th scope='row'>Forecast Period</th><td>2023 to 2033</td></tr><tr><th scope='row'>Quantitative Units</th><td>Revenue in USD Million and CAGR from 2023 to 2033</td></tr><tr><th scope='row'>Report Coverage</th><td>Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis</td></tr><tr><th scope='row'>Segments Covered</th><td><ul><li>Drug Class</li><li>Route of Administration</li><li>Distribution Channel</li><li>Region</li></ul></td></tr><tr><th scope='row'>Regions Covered</th><td><ul><li>North America</li><li>Latin America</li><li>Europe</li><li>South Asia</li><li>East Asia</li><li>Oceania</li><li>Middle East &amp; Africa</li></ul></td></tr><tr><th scope='row'>Key Countries Profiled</th><td><ul><li>USA</li><li>Canada</li><li>Brazil</li><li>Mexico</li><li>Germany</li><li>United kingdom</li><li>France</li><li>Spain</li><li>Italy</li><li>India</li><li>Malaysia</li><li>Singapore</li><li>Thailand</li><li>China</li><li>Japan</li><li>South Korea</li><li>Austria</li><li>New Zealand</li><li>GCC Countries</li><li>South Africa</li><li>Israel</li></ul></td></tr><tr><th scope='row'>Key Companies Profiled</th><td><ul><li>Alnylam Pharmaceuticals, Inc.</li><li>Orphalan</li><li>AstraZeneca</li><li>Vivet Therapeutics</li><li>Pfizer Inc.</li><li>Ultragenyx Pharmaceutical</li><li>Valeant Pharmaceuticals International, Inc.</li><li>Noblepharma Co., Ltd.</li><li>Merck &amp; Co., Inc.</li><li>Teva Pharmaceuticals</li></ul></td></tr><tr><th scope='row'>Customization</th><td>Available Upon Request</td></tr></tbody></table>

<p>全球强特瑞沙兰市场在2022年实现了60亿美元的市值，预计在2023至2033年的预测期内，通过实现12%的复合年增长率（CAGR），将达到208.7亿美元的市值。市场的扩张归功于强特瑞沙兰，它为具有遗传性转甲状腺素蛋白介导的淀粉样变（hATTR）的个体提供了新的治疗选择和乐观的前景。在2018年至2022年的历史时期，强特瑞沙兰市场的复合年增长率（CAGR）为5.1%。</p><table><tbody><tr><th scope='row'>报告属性</th><td>详细信息</td></tr><tr><th scope='row'>预计2023年市场价值</th><td>671.96亿美元</td></tr><tr><th scope='row'>预测2033年市场价值</th><td>208.7亿美元</td></tr><tr><th scope='row'>预测期增长速率</th><td>2023至2033年12%的复合年增长率（CAGR）</td></tr></tbody></table><p>报告范围</p><table><tbody><tr><th scope='row'>报告属性</th><td>详细信息</td></tr><tr><th scope='row'>2023年市场价值</th><td>6.7196亿美元</td></tr><tr><th scope='row'>2033年市场价值</th><td>20.87亿美元</td></tr><tr><th scope='row'>增长率</th><td>2023至2033年12%的复合年增长率（CAGR）</td></tr><tr><th scope='row'>估算基准年</th><td>2022年</td></tr><tr><th scope='row'>历史数据</th><td>2018至2022年</td></tr><tr><th scope='row'>预测期</th><td>2023至2033年</td></tr><tr><th scope='row'>量化单位</th><td>以百万美元计的收入和2023至2033年的复合年增长率（CAGR）</td></tr><tr><th scope='row'>报告覆盖范围</th><td>收入预测、体积预测、公司排名、竞争格局、增长因素、趋势和定价分析</td></tr><tr><th scope='row'>涵盖的细分市场</th><td><ul><li>药物类别</li><li>给药途径</li><li>分销渠道</li><li>地区</li></ul></td></tr><tr><th scope='row'>涵盖的地区</th><td><ul><li>北美</li><li>拉丁美洲</li><li>欧洲</li><li>南亚</li><li>东亚</li><li>大洋洲</li><li>中东及非洲</li></ul></td></tr><tr><th scope='row'>主要国家概述</th><td><ul><li>美国</li><li>加拿大</li><li>巴西</li><li>墨西哥</li><li>德国</li><li>英国</li><li>法国</li><li>西班牙</li><li>意大利</li><li>印度</li><li>马来西亚</li><li>新加坡</li><li>泰国</li><li>中国</li><li>日本</li><li>韩国</li><li>奥地利</li><li>新西兰</li><li>GCC国家</li><li>南非</li><li>以色列</li></ul></td></tr><tr><th scope='row'>主要公司概述</th><td><ul><li>Alnylam Pharmaceuticals, Inc.</li><li>Orphalan</li><li>AstraZeneca</li><li>Vivet Therapeutics</li><li>Pfizer Inc.</li><li>Ultragenyx Pharmaceutical</li><li>Valeant Pharmaceuticals International, Inc.</li><li>Noblepharma Co., Ltd.</li><li>Merck &amp; Co., Inc.</li><li>Teva Pharmaceuticals</li></ul></td></tr><tr><th scope='row'>定制服务</th><td>可根据要求提供</td></tr></tbody></table>